Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.

Muraviov and Muraviova are asking for further1 elucidation of the chosen endpoints and a more detailed characterisation of the included patients in our study of canakinumab for the treatment of patients with adult-onset Still’s disease (AOSD) with articular involvement.2\n\nAs mentioned in our previous communication, at the time of Canakinumab for treatment of adult ONset StIll’s Disease to achiEve Reduction of arthritic manifestation (CONSIDER) trial conception in 2012, there were no approved drugs and no validated scores available for AOSD. On the other hand, accumulating evidence suggested that inhibition of Interleukin-1 (IL1) could be beneficial for the patients.2–5 Thus, our aim was to investigate the effects of canakinumab in a controlled setting to provide convincing data, which could even be useful for regulatory …